Lupin, one of the leading pharmaceutical companies in India, witnessed a rise in share price on Thursday after the company has reportedly hiked price of its generic diabetes drug Fortamet by three times for 500 mg and 1000 mg variants. Despite the price hike, the company's drug is still 15% cheaper than its innovator.

Shares of Lupin are trading at Rs 1,982, up Rs 60.7, or 3.16% at the Bombay Stock Exchange (BSE) on Thursday at 1 p.m.

Total volume of shares traded on the bourses today was lower by 2.48% to 1,190,860 compared with 22-day average volume of 1,221,173.